My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: Merck Shingles Vaccine V212-011-00
Title:

A Phase III, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of V212 in Adults with Solid Tumor or Hematologic Malignancy

Description:

The purpose of this study is to test the safety and tolerability of the study vaccine, V212 in prevention of shingles in subjects with solid tumor malignancy or hematologic malignancy. In addition this study will evaluate the effectiveness of the study vaccine, V212, as compared to placebo (look-alike vaccine with no active ingredients) in the prevention of shingles in subjects with solid tumor malignancy or hematologic malignancy. The study vaccine (V212) is a varicella-zoster virus (VZV) vaccine that has been treated with a low dose of radiation to kill the virus, producing a non-live virus vaccine.

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD
Disease:
Cancer Prevention
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list